Jinhan Xie

Jinhan Xie

Auto-generated profile, based on publicly available information

Jinhan Xie

Children’s Cancer Institute 1 , Lowy Cancer Research Centre, UNSW Sydney, Sydney, Australia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2023 in Cancer Research
Verified
Journal Article
Open access
PDF file
CMChelsea Mayoh
Chelsea Mayoh
JMJie Mao
Jie Mao
JXJinhan Xie
Jinhan Xie
GTGabor Tax
Gabor Tax
SCShu-Oi Chow
Shu-Oi Chow
EDEmmy Dolman
Emmy Dolman
For one-third of patients with pediatric cancer enrolled in precision medicine programs, molecular profiling does not result in a therapeutic recommendation. To identify potential strategies for treating these high-risk pediatric patients, we performed in vitro screening of 125 patient-derived samples against a library of 126 anticancer drugs. Tumor cell expansion did not influence drug responses, and 82% of the screens on expanded tumor cells were completed while the patients were still under clinical care. High-throughput drug screening (HTS) confirmed known associations between activating genomic alterations in NTRK, BRAF, and ALK and responses to matching targeted drugs. The in vitro results were further validated in patient-derived xenograft models in vivo and were consistent with clinical responses in treated patients. In addition, effective combinations could be predicted by correlating sensitivity profiles between drugs. Furthermore, molecular integration with HTS identified biomarkers of sensitivity to WEE1 and MEK inhibition. Incorporating HTS into precision medicine programs is a powerful tool to accelerate the improved identification of effective biomarker-driven therapeutic strategies for treating high-risk pediatric cancers. Significance: Integrating HTS with molecular profiling is a powerful tool for expanding precision medicine to support drug treatment recommendations and broaden the therapeutic options available to high-risk pediatric cancers.

27 May 2021 in Cancer Cytopathology
Verified
Journal Article
Closed access
PDF file
JXJinhan Xie
Jinhan Xie
AKAmit Kumar
Amit Kumar
MDM Emmy M Dolman
M Emmy M Dolman
CMChelsea Mayoh
Chelsea Mayoh
DKDong-Anh Khuong-Quang
Dong-Anh Khuong-Quang
AGAndrew J Gifford
Andrew J Gifford

10 July 2025 in Cancer Research Communications
Verified
Journal Article
Open access
NANadine Azzam
Nadine Azzam
JFJamie I. Fletcher
Jamie I. Fletcher
NMNicole Melong
Nicole Melong
LLLoretta Lau
Loretta Lau
EDEmmy Dolman
Emmy Dolman
JBJason N. Berman
Jason N. Berman
Despite advances in precision medicine, 30% of high-risk pediatric cancers lack an actionable molecular target, hindering effective treatment and impacting survival outcomes. While mouse patient-derived xenograft (PDX) models offer additional insights into clinical drug responses, delivering findings from these models within a clinically actionable timeframe remains challenging. This international collaboration between two national precision medicine programs demonstrates proof-of-principle that individualized larval zebrafish PDXs can robustly and rapidly assess clinical responses of high-risk child cancer patients. Retrospective zebrafish PDX testing was performed on tumor samples from ten pediatric patients with high-risk cancers. Drug responses in zebrafish models were correlated with clinical responses for each patient and directly compared with responses in cognate mouse PDX models. Responses to conventional and targeted therapies, administered as single agents or in combinations, were assessed. Zebrafish PDXs were successfully established from all ten patients and provided robust drug response data in every case, including from 3 patients whose tumor samples could not be engrafted in mice. Remarkably, zebrafish models accurately recapitulated patient responses for 11 of 12 treatment regimens. These findings highlight the potential of larval zebrafish PDX models to provide real-time, clinically relevant drug response data, supporting their potential use in prospective precision medicine studies.

25 July 2025
Verified
Other
Open access
NANadine Azzam
Nadine Azzam
JFJamie I. Fletcher
Jamie I. Fletcher
NMNicole Melong
Nicole Melong
LLLoretta Lau
Loretta Lau
EDEmmy Dolman
Emmy Dolman
JBJason N. Berman
Jason N. Berman
Larval zebrafish PDX development: sample source and cell viability

25 July 2025
Verified
Other
Open access
NANadine Azzam
Nadine Azzam
JFJamie I. Fletcher
Jamie I. Fletcher
NMNicole Melong
Nicole Melong
LLLoretta Lau
Loretta Lau
EDEmmy Dolman
Emmy Dolman
JBJason N. Berman
Jason N. Berman
Mouse and larval zebrafish PDX drug efficacy for responsive patients. A to D, Patient information, alongside mouse PDX waterfall plot of maximum tumor regression, and larval zebrafish tumor cell numbers for each therapy for Ewing sarcoma zccs505 (A), anaplastic large cell lymphoma zccs250 (B), neuroblastoma zccs51 (C), and Ewing sarcoma zccs59 (D). For mouse PDX data, colored columns represent individual mice. For larval zebrafish data, error bars represent mean ± SEM, each colored dot represents an individual larva, and a threshold is based on SEM of 1 dpi. Statistical analysis was conducted using a one-way ANOVA with the Dunnett multiple comparisons test, comparing the mean of each treatment group with control (4 dpi), P values: *, < 0.05; **, < 0.01; ***, < 0.001; ****, < 0.0001. Treatments are ordered and colored the same in mouse and zebrafish studies. mut, mutant; dpi, days post-injection.

2 July 2026
Verified
Other
Open access
AFAshleigh M. Fordham
Ashleigh M. Fordham
LBLauren M. Brown
Lauren M. Brown
CMChelsea Mayoh
Chelsea Mayoh
ASAlice Salib
Alice Salib
ZBZara A. Barger
Zara A. Barger
EFEmmy D.G. Fleuren
Emmy D.G. Fleuren
A) PDGFA-D ligand RNA expression (TPM) across sarcoma samples, rank ordered on total PDGF-expression counts. RNA expression (Z-score) for B) PTK7, C) FGFR4 and D) FGF8 in the ZERO cohort. Colors indicate specific samples as shown in legends. E-F) Correlation between E) FGFR4 (TPM) and FGFR4 copy number, or F) FGF8 (TPM) and FGF8 copy number in ZERO sarcoma patients. G) Gene set enrichment analysis (GSEA) was performed using the camera method (limma package, R) on the full transcriptomic dataset to compare FP-RMS with other sarcoma subtypes. Pathway definitions were obtained from the Reactome gene set collection (reactome.org). The analysis was conducted using default parameters and significance was assessed based on FDR-adjusted p-values. H) Heatmap illustrating single sample GSEA (ssGSEA) scores for individual sarcoma patient samples from the three FGFR4 pathways identified from (G). Colors indicate specific samples as shown in legends. EWS: Ewing sarcoma, FP-RMS: fusion-positive rhabdomyosarcoma, FN-RMS: fusion-negative rhabdomyosarcoma, OS: osteosarcoma, MRT: malignant rhabdoid tumor, MPNST: malignant peripheral nerve sheath tumor, ASPS: alveolar soft part sarcoma, AS: angiosarcoma, IFS: infantile fibrosarcoma, DSRCT: desmoplastic small round blue cell tumor, GIST: gastrointestinal stromal tumor, SynS: synovial sarcoma, GNET: gastrointestinal neuroectodermal tumor, HGU: high-grade undifferentiated sarcoma, AF: ameloblastic fibrosarcoma, CIC: CIC-rearranged sarcoma, EPI: epithelioid sarcoma, FMX: low-grade fibromyxoid sarcoma, Round cell: EWSR1-PATZ1 round cell sarcoma, desmoid: desmoid tumor.